Physician profile
Sara Ashraf
NPI 1538301817
$4,543.28
in general payments reported to CMS, 2019-2025
13 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $182 · 2021: $50.00 · 2022: $3,597 · 2023: $18.19 · 2024: $113 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,500.00 | 2022 | |
| Glaxosmithkline, LLC. | $198.76 | 2023-2025 | Ojjaara, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $182.22 | 2020 | |
| Verona Pharma, INC. | $106.24 | 2025 | Ohtuvayre |
| Amag Pharmaceuticals, INC. | $102.40 | 2019 | |
| Intuitive Surgical, INC. | $96.72 | 2022 | |
| Genentech USA, INC. | $90.70 | 2019 | |
| Celgene Corporation | $85.95 | 2019 | |
| Beigene USA, INC. | $50.00 | 2021 | |
| La Jolla Pharmaceutical Company | $45.90 | 2025 | Giapreza |
| Astrazeneca Pharmaceuticals LP | $42.83 | 2024-2025 | Enhertu |
| Janssen Pharmaceuticals, INC | $23.40 | 2024 | Xarelto |
| Janssen Biotech, INC. | $18.16 | 2025 | Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.